Efficacy and safety of low‐dose apatinib in ovarian cancer patients with platinum‐resistance or platinum‐refractoriness: A single‐center retrospective study

BACKGROUND: This study aimed to evaluate the efficacy and safety of apatinib with a low dose of 250 mg/d in the treatment of platinum‐resistant or platinum‐refractory ovarian cancer patients. METHODS: Patients with platinum‐resistant or platinum‐refractory ovarian carcinoma treated with 250 mg/d apa...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wei, Li, Ziting, Zheng, Zhong, Wu, Xiaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433830/
https://www.ncbi.nlm.nih.gov/pubmed/32627959
http://dx.doi.org/10.1002/cam4.3282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433830/
https://www.ncbi.nlm.nih.gov/pubmed/32627959
http://dx.doi.org/10.1002/cam4.3282

Ejemplares similares